Platelet-activating factor modulates pulmonary vasomotor tone in the perinatal lamb

Journal of Applied Physiology

Volumn 85, Issue 3, 1998, Pages 1079-1085

  Ibe, Basil O ^a   Hibler, Sue ^a   Raj, J Usha ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Hypoxia; Lung; Platelet activating factor antagonist; Pulmonary circulation; Pulmonary vascular resistance

Indexed keywords

BEPAFANT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; HYPOXIA; INTRAARTERIAL DRUG ADMINISTRATION; LAMB; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL;

EID: 0031666143     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1998.85.3.1079     Document Type: Article

References (35)

1. Accurso, F. J., S. H. Abman, R. B. Wilkening, G. S. Worthen, and P. Henson. Fetal pulmonary vasodilation after exogenous platelet-activating factor. J. Appl. Physiol. 70: 778-787, 1991.
2. Appleyard, C. B., and K. Hillier. Biosynthesis of platelet-activating factor in normal and inflamed human colon mucosa: evidence for the involvement of platelet-activating factor synthesis de novo in inflammatory bowel disease. Clin. Sci. (Colch.) 88: 713-717, 1995.
3. Argiolas, L., F. Fabi, and P. del Basso. Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites. Br. J. Pharmacol. 114: 203-209, 1995.
4. Bourbon, J. R., M. Rievtort, M. J. Engle, and P. M. Farrel. Utilization of glycogen for phospholipid synthesis in fetal rat lung. Biochim. Biophys. Acta 712: 382-389, 1982.
5. Bradley, L. M., R. E. Goldstein, G. Feuerstein, and J. F. Czaja. Circulatory effects of PAF-acether in newborn piglets. Am. J. Physiol. 256 (Heart Circ. Physiol. 25): H205-H212, 1989.
6. Burhop, K. E., H. Van Der Zee, R. Bizios, J. E. Kaplan, and A. B. Malik. Pulmonary vascular response to platelet-activating factor in awake sheep and the role of cyclooxygenase metabolites. Am. Rev. Respir. Dis. 134: 548-554, 1986.
7. Caplan, M. S., W. Hsueh, X.-M. Sun, S. S. Gidding, and J. R. Hageman. Circulating plasma PAF in persistent pulmonary hypertension of the newborn. Am. Rev. Respir. Dis. 142: 1258-1262, 1990.
8. Cassin, S. Role of prostaglandins and thromboxanes in the control of the pulmonary circulation of the fetus and newborn. Semin. Perinatol. 4: 101-107, 1980.
9. Chang, S. W., C. O. Feddersen, P. M. Hanson, and N. F. Voelkel. Platelet activating factor mediates pulmonary hemodynamic changes and lung injury in endotoxin treated rats. J. Clin. Invest. 79: 1498-1503, 1987.
10. Christman, B. W., P. L. Lefferts, G. A. King, and J. R. Snapper. Role of circulating platelets and granulocytes in PAF-induced pulmonary dysfunction in awake sheep. J. Appl. Physiol. 64: 2033-2041, 1988.
11. Chung, K. F. Platelet-activating factor in inflammation and pulmonary disorders. Clin. Sci. (Colch.) 83: 127-138, 1992.
12. Cornfield, D. N., B. A, Chatfield, J. A. Mcqueston, I. F. McMurtry, and S. H. Abman. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am. J. Physiol. 262 (Heart Circ. Physiol. 31): H1474-H1481, 1992.
13. 4 in pulmonary hypertension: platelet-activating factor vs. hypoxia. J. Appl. Physiol. 68: 1628-1633, 1990.
14. De Lima, W. T., F. H. Kwasniewski, P. Sirois, and S. Jancar. Studies on the mechanism of PAF-induced vasopermeability in rat lungs. Prostaglandins Leukot. Essent. Fatty Acids 52: 245-249, 1995.
15. Gao, Y., H. Zhou, and J. U. Raj. Platelet-activating factor causes relaxation of pulmonary arteries but contraction of pulmonary veins in the ferret. Am. J. Physiol. 269 (Heart Circ. Physiol. 38): H704-H709, 1995.
16. Hamasaki, Y., M. Mojarad, T. Saga, H. H. Tai, and S. I. Said. Platelet activating factor raises airway and systemic vascular pressure and induces edema in lungs perfused with platelet free solution. Am. Rev. Respir. Dis. 129: 742-746, 1984.
17. Haynes, J., S. W. Chang, K. G. Morris, and N. F. Voelkel. Platelet-activating factor antagonists increase vascular reactivity in perfused rat lungs. J. Appl. Physiol. 65: 1921-1928, 1988.
18. Heuer, H. O., J. Casal-Stenzel, G. Muacevic, and K.-H. Weber. Pharmacological activity of Bepafant (WEB-2170) a new and selective tetrazepinoic antagonist of platelet activating factor. J. Pharmacol. Exp. Ther. 255: 962-968, 1990.
19. Hoffman, D. R., C. T. Troug, and J. M. Johnston. The role of platelet-activating factor in human fetal lung maturation. Am. J. Obstet. Gynecol. 155: 70-75, 1983.
20. Jancar, S., P. Braquet, and P. Sirois. Interaction of arachidonic acid metabolites and platelet activating factor and mechanism of action in hypersensitivity reactions. Braz. J. Med. Biol. Res. 20: 487-494, 1987.
21. Leffler, C. W., J. R. Hessler, and R. S. Green. The onset of breathing at birth stimulates pulmonary vascular prostacyclin synthesis. Pediatr. Res. 18: 938-942, 1984.
22. Lepore, D. A., K. R. Knight, A. G. Stewart, M. Riccio, and W. A. Morrison. Platelet-activating factor (PAF) receptor antagonism by WEB-2170 improves the survival of ischaemic skeletal muscle. Ann. Acad. Med. Singapore 24: 63-67, 1995.
23. McMurtry. I. F., and K. G. Morris. Platelet-activating factor causes pulmonary vasodilation in the rat. Am. Rev. Respir. Dis. 134: 757-762, 1986.
24. Moore, P., H. Velvis, J. R. Fineman, S. J. Soifer, and M. A. Heymann. EDRF inhibition attenuates the increase in pulmonary blood flow due to oxygen ventilation in fetal lambs. J. Appl. Physiol. 73: 2151-2157, 1992.
25. Mustafa, S. B., K. M. Howard, and M. S. Olson. Platelet-activating factor augments lipopolysaccharide-induced nitric oxide formation by rat Kupffer cells. Hepatology 23: 1622-1630, 1996.
26. Olson, N. C., K. T. Kruse-Elliot, and L. W. Johnson. Effect of 5-lipoxygenase and cyclooxygenase blockade on porcine hemodynamics during continuos infusion of platelet-activating factor. Prostaglandins Leukot. Essent. Fatty Acids 49: 549-559, 1993.
27. Ramirez, M. M., S. M. Quardt, D. Kim, H. Oshiro, M. Minnicozzi, and W. N. Duran. Platelet activating factor modulates microvascular permeability through nitric oxide synthesis. Microvasc. Res. 50: 223-243, 1995.
28. Rudolph, A. M. Fetal and neonatal pulmonary circulation. Am. Rev. Respir. Dis. 115: 11-18, 1977.
29. Salva, A. M. L., B. O. Ibe, E. Cliborn, G. Reyes, and J. U. Raj. Hypoxia attenuates metabolism of platelet activating factor by fetal and newborn lamb lungs. J. Lipid Res. 37: 783-789, 1996.
30. Sansoucie, D. A., and T. A. Cavaliere. Transition from fetal to extrauterine circulation. Neonatal Network 16: 5-12, 1997.
31. Snyder, F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem. J. 305: 689-705, 1995.
32. Toyofuku, T., T. Kobayashi, S. Koyama, and S. Kusama. Pulmonary vascular response to platelet-activating factor in conscious sheep. Am. J. Physiol. 255 (Heart Circ. Physiol. 24): H434-H440, 1988.
33. Uhlig, S., L. Wolin, and A. Wendel. Contributions of thromboxane and leukotrienes to PAF-induced impairment of lung function in the rat. J. Appl. Physiol. 77: 262-269, 1994.
34. Valone, F. H. Platelet-activating factor binding to specific cell membrane receptors. In: Platelet-Activating Factor and Related Lipid Mediators, edited by F. Snyder. New York: Plenum, 1987, p. 137-151.
35. Wilson, D. V., S. W. Eberhart, N. E. Robinson, R. Rice, and P. R. Gray. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB-2086. Am. J. Vet. Res. 54: 274-279, 1993.